Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EIF2AK3 | Q9NZJ5 | 4/20 | 0.36 |
| ▸ | EIF2AK1 | Q9BQI3 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7433118 | 0.96 | RIPK1 (0.39) | RIPK1ROCK1CYP11B1CYP11B2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5208180 | 0.96 | RIPK1 (0.42) | RIPK1ROCK1CYP11B1CYP11B2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5210860 | 0.95 | RIPK1 (0.42) | RIPK1ROCK1CYP11B1CYP11B2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5213690 | 0.94 | CYP11B1 (0.41) | RIPK1ROCK1CYP11B1CYP11B2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5212450 | 0.91 | RIPK1 (0.39) | RIPK1ROCK1ALDH1A1ACHEFOLH1 | |
| Trifluoroacetic Acid SCHEMBL5211441 | 0.90 | RIPK1 (0.38) | RIPK1ROCK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5213696 | 0.90 | ROCK1 (0.39) | RIPK1ROCK1CYP11B1CYP11B2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5214210 | 0.88 | ROCK1 (0.40) | RIPK1ROCK1ALDH1A1FOLH1NPY2R | |
| Trifluoroacetic Acid SCHEMBL5210720 | 0.88 | HSD17B3 (0.38) | RIPK1ALDH1A1NPY2R | |
| Trifluoroacetic Acid SCHEMBL5210137 | 0.88 | RIPK1 (0.37) | RIPK1ROCK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | RIPK1 1724/4885ROCK1 1847/4885CYP11B1 3377/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | RIPK1 1933/4885ROCK1 1504/4885CYP11B1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.